#Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market

[alicesara611]

Beyond Symptom Relief: Examining the Evolution of Chemotherapy Induced Nausea and Vomiting Drugs by 2030

The global chemotherapy-induced nausea and vomiting (CINV) drugs market is likely to reach value at US$ 2,558.12 million in 2023 and is expected to reach US$ 4,672.82 million by 2030, growing at a CAGR of 6.6% from 2023 to 2030.

Chemotherapy-induced nausea and vomiting (CINV) is a common and debilitating side effect of cancer treatment. It can significantly impact a patient's quality of life and adherence to chemotherapy. The global Chemotherapy-induced nausea and vomiting drugs market is projected to witness significant growth in the coming years, driven by the increasing prevalence of cancer, rising demand for effective Chemotherapy-induced nausea and vomiting control, and advancements in drug development.

Get Recently Updated Report of Market as Sample Copy! https://absolutemarketresearch.com/Global-Chemotherapy-Induced-Nausea-and-Vomiting-(CINV)-Drugs-Market/1230/request-sample

Chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to better manage these symptoms in a large portion of patients. Efficient mediation of these unpleasant and sometimes crippling symptoms results in increased quality of life for the patient, and better overall health of the patient, and, due to better patient tolerance, more effective treatment cycles.

Types of Chemotherapy-induced nausea and vomiting Drugs:

Chemotherapy-induced nausea and vomiting drugs can be broadly classified into three main categories:

5-HT3 Receptor Antagonists: These drugs block the action of serotonin, a neurotransmitter involved in nausea and vomiting. Examples include ondansetron (Zofran), granisetron (Kytril), dolasetron (Anzemet), and palonosetron (Aloxi).

NK1 Receptor Antagonists: These drugs block the action of substance P, another neurotransmitter involved in nausea and vomiting. Examples include aprepitant (Emend) and fosaprepitant (Apreva).

Corticosteroids: These drugs have anti-inflammatory and antiemetic properties. Dexamethasone is the most commonly used corticosteroid for Chemotherapy-induced nausea and vomiting.

Choosing the Right Chemotherapy-induced nausea and vomiting Drugs:

The choice of Chemotherapy-induced nausea and vomiting drugs depends on several factors, including the type of chemotherapy, the patient's risk of Chemotherapy-induced nausea and vomiting, and any other medical conditions the patient may have.

For patients receiving highly emetogenic chemotherapy (HEC), which has the highest risk of causing CINV, a combination of a 5-HT3 receptor antagonist, an NK1 receptor antagonist, and dexamethasone is recommended. For patients receiving moderately emetogenic chemotherapy (MEC), a 5-HT3 receptor antagonist with dexamethasone is usually sufficient. For patients receiving low-emetogenic chemotherapy, dexamethasone alone may be enough.

Side Effects of Chemotherapy-induced nausea and vomiting Drugs:

Chemotherapy-induced nausea and vomiting drugs are generally well-tolerated, but they can cause side effects such as headache, constipation, and fatigue. Some drugs, such as aprepitant, can also cause dizziness and vertigo.

Overall, Chemotherapy-induced nausea and vomiting drugs play an important role in improving the quality of life for cancer patients and helping them continue their chemotherapy treatment.

Key Market Drivers:

Rising Prevalence of Cancer: The increasing incidence of cancer is a major driver of the Chemotherapy-induced nausea and vomiting drugs market. As the global cancer burden continues to grow, the demand for effective Chemotherapy-induced nausea and vomiting control measures is expected to rise.

Demand for Effective CINV Control: Chemotherapy-induced nausea and vomiting can significantly impair a patient's quality of life and adherence to chemotherapy. The growing demand for effective Chemotherapy-induced nausea and vomiting control measures is driving the development of new and more potent drugs.

Advancements in Drug Development: Continuous advancements in drug development are leading to the introduction of novel and more targeted Chemotherapy-induced nausea and vomiting drugs. These drugs offer improved efficacy and reduced side effects compared to traditional treatments.

Key Takeaways:

The global Chemotherapy-induced nausea and vomiting (CINV) drugs market is likely to reach value at US$ 2,558.12 million in 2023 and is expected to reach US$ 4,672.82 million by 2030, growing at a CAGR of 6.6% from 2023 to 2030.

The growth of the market is driven by the increasing prevalence of cancer, the rising adoption of chemotherapy, and the growing demand for effective Chemotherapy-induced nausea and vomiting prophylaxis and treatment.

The acute emesis segment is expected to dominate the market due to the advancement in chemotherapy and the increasing use of highly emetogenic chemotherapy (HEC) drugs.

North America is expected to hold the largest market share due to the high prevalence of cancer, the early adoption of new technologies, and the strong presence of key players in the region.

Regional Outlook:

North America is expected to hold the largest market share, accounting for approximately 38% of the global market in 2030.

Europe is expected to be the second-largest market, followed by Asia Pacific.

The growth in the Asia Pacific market is expected to be driven by the increasing prevalence of cancer, the growing demand for affordable Chemotherapy-induced nausea and vomiting drugs, and the expanding healthcare infrastructure in the region.

Key Players:

GlaxoSmithKline plc

Pfizer Inc.

Novartis AG

Sanofi SA

Merck & Co., Inc.

Eisai Co., Ltd.

AstraZeneca plc

Daiichi Sankyo Co., Ltd.

Cosmo Pharmaceuticals Ltd.

Heron Therapeutics, Inc.

Segmentation:

By Product:

5-HT3 antagonists

NK1 receptor antagonists

Steroids

Antiemetics

Others

By End User:

Hospitals

Cancer centers

Ambulatory care centers

Others

By Type:

Acute emesis

Delayed emesis

Breakthrough emesis

[heathcareforallworld]

Global Metoclopramide Market Trends: Analyzing the Future Through 2032

Introduction

Metoclopramide is a well-known medication used to treat various gastrointestinal disorders, including nausea, vomiting, and gastroparesis. It is commonly prescribed for conditions where the stomach fails to empty its contents quickly enough, leading to nausea and vomiting. With its widespread use in treating gastrointestinal issues, the global metoclopramide market is poised for steady growth in the coming years. This article provides a comprehensive analysis of the metoclopramide market size, share, industry trends, and forecast through 2032.

Market Size and Growth

Metoclopramide Market Size was estimated at 1.28 (USD Billion) in 2023. The Metoclopramide Market Industry is expected to grow from 1.31(USD Billion) in 2024 to 1.626 (USD Billion) by 2032. The metoclopramide Market CAGR (growth rate) is expected to be around 2.7% during the forecast period (2024 - 2032). Several factors contribute to this growth, including the rising prevalence of gastrointestinal disorders, increasing awareness of treatment options, and the expanding elderly population, which is more prone to such conditions.

Market Segmentation

1. By Product Type:

Tablets: Metoclopramide tablets are the most commonly prescribed form due to their ease of administration and widespread availability. This segment accounts for the largest market share and is expected to continue its dominance through 2032.

Injections: Injectable metoclopramide is used in more severe cases or when oral administration is not possible. This segment is growing steadily due to its application in emergency and hospital settings.

Oral Solution: The oral solution form of metoclopramide is particularly useful for pediatric and elderly patients who may have difficulty swallowing tablets. This segment is expected to see moderate growth over the forecast period.

2. By Application:

Nausea and Vomiting: This segment holds the largest share of the metoclopramide market. The drug is widely used to treat nausea and vomiting associated with various conditions, including chemotherapy-induced nausea, postoperative nausea, and motion sickness.

Gastroparesis: Metoclopramide is the only FDA-approved medication for diabetic gastroparesis, making this a significant segment of the market. The increasing prevalence of diabetes worldwide is expected to drive growth in this segment.

Gastroesophageal Reflux Disease (GERD): Although not the first-line treatment for GERD, metoclopramide is sometimes used in cases where other medications are ineffective, contributing to market growth.

Others: This includes applications such as functional dyspepsia and migraine-induced nausea, where metoclopramide is sometimes used off-label.

3. By Distribution Channel:

Hospital Pharmacies: Hospital pharmacies hold a significant share of the market, especially for injectable forms of metoclopramide used in acute care settings.

Retail Pharmacies: Retail pharmacies are the largest distribution channel, given the chronic nature of many conditions treated with metoclopramide.

Online Pharmacies: The rise of e-commerce and online pharmacies is contributing to the growing availability and convenience of purchasing metoclopramide, particularly in developed markets.

Regional Analysis

1. North America:

Market Share: North America leads the global metoclopramide market, with a share of approximately 45%. The region's high prevalence of gastrointestinal disorders, coupled with advanced healthcare infrastructure, drives market growth.

Trends: The increasing use of metoclopramide in treating chemotherapy-induced nausea and vomiting (CINV) and gastroparesis is a significant trend in the region.

2. Europe:

Market Share: Europe holds the second-largest market share, driven by a high burden of gastrointestinal disorders and a growing elderly population.

Trends: Stringent regulations and a focus on patient safety have led to increased scrutiny and monitoring of metoclopramide use, particularly regarding long-term usage and associated risks.

3. Asia-Pacific:

Market Share: The Asia-Pacific region is expected to register the highest growth rate during the forecast period. The large patient population, increasing healthcare access, and rising awareness about gastrointestinal health are key drivers.

Trends: The increasing incidence of diabetes in countries like India and China is expected to boost demand for metoclopramide, particularly in the treatment of diabetic gastroparesis.

4. Latin America and Middle East & Africa:

Market Share: These regions account for a smaller market share but offer significant growth potential due to improving healthcare infrastructure and increasing awareness of gastrointestinal disorders.

Trends: The growing focus on expanding access to affordable medications in these regions is likely to drive market growth.

Industry Trends

1. Increasing Prevalence of Gastrointestinal Disorders:

The rising incidence of gastrointestinal conditions such as gastroparesis, GERD, and nausea related to chemotherapy and surgery is a primary driver of the metoclopramide market.

2. Focus on Geriatric Care:

With the global population aging, there is an increasing need for medications that address age-related gastrointestinal issues. Metoclopramide's effectiveness in treating these conditions is expected to boost its demand.

3. Technological Advancements:

Ongoing research into the mechanisms of action and side effects of metoclopramide is leading to improved formulations and treatment protocols, enhancing patient outcomes and market growth.

4. Regulatory Challenges:

The long-term use of metoclopramide has been associated with side effects such as tardive dyskinesia, leading to stringent regulatory guidelines regarding its use. This has resulted in increased monitoring and a focus on safer dosing regimens.

5. Competitive Landscape:

The metoclopramide market is competitive, with key players including Teva Pharmaceutical Industries Ltd., Mylan N.V., and Baxter International Inc. Companies are focusing on expanding their product portfolios and enhancing their presence in emerging markets to drive growth.

Forecast Through 2032

The global metoclopramide market is set to experience steady growth through 2032, driven by the increasing prevalence of gastrointestinal disorders and the growing demand for effective treatments. While North America and Europe will continue to dominate the market, the Asia-Pacific region is expected to emerge as a significant growth area due to its large patient population and improving healthcare infrastructure.

In conclusion, the metoclopramide market presents numerous opportunities for growth, particularly in emerging markets. Companies operating in this space should focus on innovation, regulatory compliance, and strategic partnerships to capitalize on the opportunities presented by the increasing global demand for gastrointestinal treatments.

[infinitiresearch]

Antiemetic Drug Market| Market Size, Trends, Analysis, Growth and Forecast, 2023 – 2027

Originally published on Technavio: Antiemetic Drug Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast 2023-2027

Analyzing the antiemetic drug market across regions including North America, Europe, Asia, and the Rest of the World (ROW) provides insights into significant growth opportunities. In North America, particularly in the United States, the market is expected to witness robust growth due to factors such as the high prevalence of chemotherapy-induced nausea and vomiting (CINV) among cancer patients, increasing adoption of antiemetic drugs for postoperative nausea and vomiting (PONV), and the presence of well-established healthcare infrastructure. Additionally, the growing geriatric population, which is more prone to nausea and vomiting, further contributes to market expansion.

Similarly, in Europe, countries like Germany and the UK are key markets for antiemetic drugs. The region benefits from a strong healthcare system and high awareness about the availability of antiemetic treatments. The increasing prevalence of cancer and chemotherapy procedures, coupled with rising awareness about the management of chemotherapy-related side effects, drives market growth in these countries. Additionally, advancements in antiemetic drug formulations and the introduction of novel therapies contribute to market expansion.

In Asia, countries like China and Japan are witnessing significant growth in the antiemetic drug market. Factors such as the rising incidence of cancer, increasing healthcare expenditure, and expanding access to healthcare services drive market growth in the region. Moreover, the adoption of Western lifestyles and dietary habits leading to gastrointestinal disorders and the growing elderly population contribute to the demand for antiemetic drugs. Additionally, government initiatives to improve healthcare infrastructure and access to essential medicines further support market growth in Asia.

The Rest of the World (ROW) region presents opportunities for market players to expand their presence. Countries in Latin America, the Middle East, and Africa are witnessing increasing incidence rates of cancer and other diseases associated with nausea and vomiting. The growing recognition of the importance of managing these symptoms effectively, coupled with efforts to improve healthcare infrastructure and access to essential medicines, drives market growth in these regions.

To Learn deeper into this report , View Sample PDF

Overall, the antiemetic drug market is poised for significant growth across regions, driven by factors such as the increasing prevalence of cancer and chemotherapy procedures, rising awareness about the management of chemotherapy-related side effects, and improvements in healthcare infrastructure. Key markets such as the US, Germany, UK, China, and Japan are expected to lead the way in terms of market size and adoption rate, while emerging markets in Asia and the Rest of the World present untapped opportunities for market expansion.

For more information please contact.

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: media@technavio.com

Website: www.technavio.com/

[vanshika393]

Chemotherapy Induced Nausea And Vomiting Treatment Market - Top Trends, Demand, Share & Forecast 2030 | Credence Research

The latest market report published by Credence Research, Inc. “Global Chemotherapy Induced Nausea And Vomiting Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2023 – 2030. The global Chemotherapy-Induced Nausea and Vomiting Therapeutics Market has been steadily growing in recent years and is predicted to grow at a 6.50% CAGR between 2023 and 2030. The market is anticipated to be worth USD 9514.4 million by 2030, up from USD 5748.9 million in 2022.

The Chemotherapy Induced Nausea and Vomiting (CINV) Treatment Market refers to the pharmaceutical and medical products and services industry segment that focuses on developing, producing, and providing treatments for nausea and vomiting that are induced by chemotherapy.

Chemotherapy is a common cancer treatment that uses powerful drugs to kill or slow down the growth of cancer cells. However, a common side effect of chemotherapy is nausea and vomiting, which can be severe and debilitating for patients. The CINV treatment market is dedicated to finding effective ways to manage and alleviate these side effects, thereby improving the quality of life for cancer patients undergoing chemotherapy.

In this market, various types of medications and therapies are developed and marketed to help control and prevent CINV. These treatments may include anti-nausea drugs, antiemetic medications, and other supportive care measures. The market also includes medical devices and services related to managing CINV, such as intravenous (IV) fluids and other supportive therapies.

The goal of the CINV treatment market is to provide cancer patients with options that can help reduce or eliminate chemotherapy-induced nausea and vomiting, allowing them to better tolerate their cancer treatment and maintain their overall well-being during their cancer journey. This market plays a crucial role in improving the patient experience and ensuring that cancer treatments are as tolerable as possible.

Chemotherapy Induced Nausea And Vomiting Treatment Market Top Trends

Chemotherapy Induced Nausea And Vomiting Treatment Market is witnessing significant growth due to the increasing incidence of cancer and the rising adoption of chemotherapy as a primary treatment option. Chemotherapy-induced nausea and vomiting (CINV) are common side effects experienced by cancer patients undergoing chemotherapy, often causing discomfort and affecting their quality of life.

Therefore, the demand for effective CINV treatments has led to extensive research and development, resulting in innovative pharmaceutical options such as antiemetic drugs, cannabinoids, corticosteroids, 5-HT3 receptor antagonists, and NK1 receptor antagonists. Moreover, advancements in drug administration techniques like intravenous infusion systems have enhanced patient comfort during therapy sessions. The market also benefits from favorable reimbursement policies offered by governments to support cancer care services. Additionally, ongoing clinical trials focusing on personalized medicine approaches hold immense potential for further innovation in CINV treatment options.

Browse 247 pages report Chemotherapy Induced Nausea And Vomiting Treatment Market By Patient Risk Profile (High-Risk Patients, Low-Risk Patients, Chemotherapy Regimen) By Administration Route (Oral Medications, Intravenous (IV) Medications) By Branded vs. Generic Products (Branded Medications, Generic Medications)-Growth, Future Prospects & Competitive Analysis, 2016 – 2030 - https://www.credenceresearch.com/report/chemotherapy-induced-nausea-and-vomiting-treatment-market

Some of the major players in the market and their market share are as follows:

Kyowa Kirin, Inc.

Pfizer Inc.

GlaxoSmithKline plc.

AbbVie Inc. (Allergan plc)

Merck & Co., Inc.

Bausch Health Companies Inc.

Novartis AG

Ono Pharmaceutical Co., Ltd.

Chemotherapy Induced Nausea And Vomiting Treatment Market key offerings

The Chemotherapy Induced Nausea And Vomiting Treatment Market offers various key offerings to address the specific needs of patients undergoing chemotherapy. This market focuses on providing effective solutions to alleviate the distressing symptoms of nausea and vomiting that commonly occur during cancer treatment. Pharmaceutical companies invest in extensive research and development activities to develop innovative antiemetic drugs, which are at the forefront of this market's offerings.

These medications work by targeting specific receptors in the central nervous system responsible for triggering nausea and vomiting mechanisms, thus providing relief to cancer patients. Additionally, medical devices such as neurostimulation devices are gaining prominence within this market segment. They employ electrical impulses to stimulate certain nerves and help control nausea or vomiting symptoms effectively. Furthermore, personalized medicine approaches tailored towards individual patients' conditions are emerging as a prominent offering within this market.

By utilizing genetic profiling and identifying biomarkers associated with chemotherapy-induced side effects, healthcare providers can customize treatment plans for better patient outcomes. Overall, this burgeoning Chemotherapy Induced Nausea And Vomiting Treatment Market aims to enhance the quality of life for individuals battling cancer by addressing their specific needs comprehensively using cutting-edge advancements in drug therapies, medical devices, and precision medicine techniques

Why to Buy This Report-

The report provides a qualitative as well as quantitative analysis of the global Chemotherapy Induced Nausea And Vomiting Treatment Market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the historical period from 2016-2020, the base year- 2021, and the projection period 2022-2028.

The report includes information on the competitive landscape, such as how the market's top competitors operate at the global, regional, and country levels.

Major nations in each region with their import/export statistics

The global Chemotherapy Induced Nausea And Vomiting Treatment Market report also includes the analysis of the market at a global, regional, and country-level along with key market trends, major players analysis, market growth strategies, and key application areas.

Browse Complete Report- https://www.credenceresearch.com/report/chemotherapy-induced-nausea-and-vomiting-treatment-market

Visit our Website- https://www.credenceresearch.com/

Related Reports- https://www.credenceresearch.com/report/controlled-substance-market

Browse Our Blog- https://www.linkedin.com/pulse/chemotherapy-induced-nausea-vomiting-treatment-market-shukla

About Us -

Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 10,000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives. For nearly a century, we’ve built a company well-prepared for this task.

Contact Us:

Office No 3 Second Floor, Abhilasha Bhawan, Pinto Park, Gwalior [M.P] 474005 India

[delicatemagazinedreamer]

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market Is Estimated To Witness High Growth Owing To Increasing Demand For Efficient Nausea

The global Cancer Chemotherapy Associated Nausea and Vomiting (CINV) therapeutics market is estimated to be valued at US$3,071.1 million in 2023 and is expected to exhibit a CAGR of 5.7% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Cancer chemotherapy often leads to side effects such as nausea and vomiting, which significantly impact the quality of life for cancer patients. In order to manage these symptoms effectively, the demand for CINV therapeutics is increasing. These therapeutics aim to control and prevent chemotherapy-induced nausea and vomiting, improving patient comfort during treatment. The market offers various products including antiemetic drugs, cannabinoids, and other supportive care products that help alleviate these side effects. Market Key Trends: One key trend observed in the global CINV therapeutics market is the shift towards personalized medicine. With advancements in understanding the genetic makeup of individuals, healthcare providers are able to tailor treatment plans specifically for each patient. This helps in identifying the optimal antiemetic drugs and dosages, making them more effective in managing CINV. For example, the use of genetic testing to determine an individual's susceptibility to CINV can aid in selecting the most appropriate antiemetic regimen. PEST Analysis: Political: Governments worldwide are focusing on improving access to cancer treatments and supportive care for patients. This has led to various initiatives aimed at reducing the financial burden on cancer patients and promoting research and development in the field. Economic: The increasing prevalence of cancer globally, coupled with rising healthcare expenditure, is driving the demand for CINV therapeutics. Additionally, advancements in healthcare infrastructure and reimbursement policies are further supporting market growth. Social: Cancer is a major healthcare concern, and the need for effective management of chemotherapy-induced side effects is widely recognized. This has created a strong demand for CINV therapeutics, as patients and healthcare providers seek ways to improve treatment outcomes and patient well-being. Technological: Technological advancements in the field of genomics and molecular biology have opened up new possibilities for personalized medicine. This has led to the development of targeted therapies and the ability to identify genetic markers that can predict an individual's response to antiemetic drugs. Key Takeaways: - The global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market Trend is expected to witness high growth, exhibiting a 5.7% CAGR over the forecast period. This can be attributed to increasing demand for more efficient nausea and vomiting management solutions. - Regionally, North America is anticipated to dominate the market due to factors such as advanced healthcare infrastructure, favorable reimbursement policies, and a high prevalence of cancer. However, the Asia Pacific region is projected to be the fastest-growing market, driven by improving healthcare infrastructure and a rising geriatric population. - Key players operating in the global CINV therapeutics market include Johnson & Johnson Services, Inc., Teleflex Incorporated, Cooper Surgical, Inc., Genicon, Medtronic, B. Braun SE, Applied Medical Resources Corporation, LaproSurge, Purple Surgical, CONMED, Hangzhou Boer Medical Instruments Co., Ltd., Duomed, Changzhou Cheayoo Medical Devices Co., Ltd., and Tianjin Zhichao Medical Technology Co., Ltd.

[megharesearch]

The latest report on the Worldwide Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Report is the more professional in-depth of this Industry is providers the status and forecast, categorizes, market size (value & volume) by type, application, region and Forecast 2023 - 2030.

[pharmaresearchdata]

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Opportunities, Business Size with Expansion Plans Forecast to 2022-2029

The Report Title Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market is one of the most comprehensive and important additions to the pharmaresearchconsulting. Provides detailed research and analysis of key aspects of the global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market. Market analysts write in-depth information provided in this report is a complete analysis of the Market, providing leading growth drivers, restraints, challenges, trends, and opportunities. Market participants can use analysis for market dynamics to plan effective growth strategies and prepare for future challenges. Each trend of the global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market is carefully analyzed and studied by market analysts.

Explore the full report with detailed TOC here:

The global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market size is expected to expand at a CAGR of 8.56% during 2022-2029.

[vijayanger12]

The global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market size is estimated to be worth US$ 2066 million in 2021 and is forecast to a readjusted size of US$ 2783.8 million by 2030 with a CAGR of 4.3% during the forecast period 2022-2030.

[bearni]

Global Chemotherapy Induced Nausea And Vomiting (CINV) Drugs Market By Type (Aloxi,Zofran Generic,Kytril Generic,Emend,Akynzeo,SUSTOL,Rolapitant), By Application (Acute CINVDelayed CINV), By Country, And Manufacture – Industry Segment, Competition Scenario And Forecast By 2029

Industry analysis and future outlook on Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Global Market brings a systematic perspective of the market execution and assists in strategic decision making for worldwide and additionally the regional situation. Detailed sections provides in-depth arrangement, the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs contemplate that make sense of different perspectives relating to the global market. To begin with, the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market definition, applications, arrangement, and industry esteem chain structure are incorporated into the answer, to target gathering of people on restricting Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market elements including drivers, limitations, openings, patterns, applications, topographical/local Chemotherapy Induced Nausea and Vomiting (CINV) Drugs markets, and aggressive scene.

Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Industry Market was valued at USD XX Million in the year 2020. The market is further estimated to grow at a CAGR of XX% from 2020 to reach USD XX Million by the year 2029.

Get Quick Free Sample Brochure report at: https://www.globalresearchview.com/report/global-chemotherapy-induced-nausea-and-v/GRV55372/request-sample/

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market rivalry by top makers/players, with Chemotherapy Induced Nausea and Vomiting (CINV) Drugs deals volume, Value (USD/Unit), Revenue (Mn/Bn USD) and market size for every producer/player; the significant players include:

GlaxoSmithKline Helsinn Heron Therapeutics Merck Tesaro

Worldwide Chemotherapy Induced Nausea and Vomiting (CINV) Drugs statistical surveying report uncovers that the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs business will develop with pivotal CAGR over the estimated forecast period of 2021 and 2029. The global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market in forecast years 2021-2029, is expected to hit Mn/Bn$ XX USD by 2029. The Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market gives broad development openings over the both created and creating economies. Further, the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs business sectors could profit without a doubt from the expanding interest to bring down Chemotherapy Induced Nausea and Vomiting (CINV) Drugs expenses of treatment over the globe.

Inquiry for Buying report to get customization at: https://www.globalresearchview.com/report/global-chemotherapy-induced-nausea-and-v/GRV55372/inquiry

Key Highlights of the Report:

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Report provides forecast and industry outlook for the period of 2021-2029 with 2020 as the base year and covering historic data for years 2015-2019.

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market outlook with Porter’s 5 Forces Analysis will provide market dynamics (Drivers, Restraints, Opportunities & Threats).

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Competitive landscape section gives you the competitive edge over other key players in the market (Key Business Strategies, Recent Development M&A, Company Overview, Products/Services Portfolio & Financial Overview).

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Technological Scenarios & Expected Developments.

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs End-Use Industry & Consumer Behaviour Trends.

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Export-Import Scenario.

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Regulatory Policies across each region.

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs In-depth analysis on Industry Trends & Dynamics across each segment covered in the report.

Based on Type, Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market report shows development rate of each type, covers:

Aloxi Zofran Generic Kytril Generic Emend Akynzeo SUSTOL Rolapitant

End clients/applications, Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market report centers around the status and viewpoint for best applications/end clients, development rate for every application, this can be isolated into:

Acute CINV Delayed CINV

Access More Information at: https://www.globalresearchview.com/report/global-chemotherapy-induced-nausea-and-v/GRV55372

In conclusion, the global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs industry report unveils research finding, outcomes, conclusions. Likewise, disclose various Chemotherapy Induced Nausea and Vomiting (CINV) Drugs data sources, traders/vendors, suppliers, manufacturers, sales channel, and addendum. In short, the overall Chemotherapy Induced Nausea and Vomiting (CINV) Drugs report is a lucrative document for people implicated in Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market.

Global Impact of COVID-19 Analysis:

COVID19 is an unrivaled global public health emergency that affects almost every industry, so the projected long-term impact will affect industry growth over the forecast period. The report provides insights into COVID19, taking into account changes in consumer behavior and demand, purchasing behavior, supply chain diversion, the dynamics of current market forces, and significant government intervention. Insights, analysis, estimates and forecasts considering the impact of COVID19 on the market.

About Us:

GlobalResearchView (GRV) is one of the leading market research company which aims to serve the most excellent research to the various sectors of business. We are prominent in satisfying all kinds of market research needs.

Contact US:

Jennifer Da (Head Global Business Development) – Global Research View(GRV) 701, Milton Avenue, East Ham,London. United kingdom. Pincode – 4E6 1BN Email: Jennifer@globalresearchview.com Websites:  www.globalresearchview.com Tel: +44 020 8638 7098

[vivekbajaj-grs]

Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market by Player, Region, Type, Application and Sales Channel 2021-2030

This report studies the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market, covering market size for segment by type (5-HT3 Inhibitors, NK1 Inhibitors, etc.), by application (Highly Emetogenic Chemotherapy, Moderately Emetogenic Chemotherapy, etc.), by Sales Channel (Direct Channel, Distribution Channel), by player (Merck, Eisai, Mundipharma, Qilu Pharma, Teva, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa).

Since the pandemic of COVID-19 is still raging, The COVID-19 will have a certain impact on this global market. This research covers COVID-19 impacts on the upstream, midstream and downstream industries. Moreover, this research provides an in-depth market evaluation by highlighting information on various aspects covering market dynamics like drivers, barriers, opportunities, threats, and industry news & trends.

Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-chemotherapy-induced-nausea-vomiting-drugs-2021-2030-429

This report provides detailed historical analysis of global market for Chemotherapy Induced Nausea and Vomiting (CINV) Drugs from 2015-2020, and provides extensive market forecasts from 2021-2030 by region/country and subsectors. It covers the sales volume, price, revenue, gross margin, historical growth and future perspectives in the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market.

Leading players of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs including:

Merck

Eisai

Mundipharma

Qilu Pharma

Teva

Novartis

Heron Therapeutics

Roche

Mylan

Tesaro

Market split by Type, can be divided into:

5-HT3 Inhibitors

NK1 Inhibitors

Other

Market split by Application, can be divided into:

Highly Emetogenic Chemotherapy

Moderately Emetogenic Chemotherapy

Low Emetogenic Chemotherapy

Other

Market split by Sales Channel, can be divided into:

Direct Channel

Distribution Channel

Market segment by Region/Country including:

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Spain etc.)

Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)

South America (Brazil, Argentina and Colombia etc.)

Middle East & Africa (South Africa, UAE and Saudi Arabia etc.)

If you have any special requirements, please let us know and we can provide you the customized report as you want.

Get the Complete Report & TOC @ https://www.grandresearchstore.com/life-sciences/global-chemotherapy-induced-nausea-vomiting-drugs-2021-2030-429

Table of content

Table of Contents Chapter 1 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Overview 1.1 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Definition 1.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Size Status and Outlook (2015-2030) 1.3 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Size Comparison by Region (2015-2030) 1.4 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Size Comparison by Type (2015-2030) 1.5 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Size Comparison by Application (2015-2030) 1.6 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Size Comparison by Sales Channel (2015-2030) 1.7 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Dynamics (COVID-19 Impacts) 1.7.1 Market Drivers/Opportunities 1.7.2 Market Challenges/Risks 1.7.3 Market News (Mergers/Acquisitions/Expansion) 1.7.4 COVID-19 Impacts on Current Market 1.7.5 Post-Strategies of COVID-19 Outbreak Chapter 2 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Segment Analysis by Player 2.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales and Market Share by Player (2018-2020) 2.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Revenue and Market Share by Player (2018-2020) 2.3 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drug

CONTACT US: 276 5th Avenue, New York , NY 10001,United States International: (+1) 646 781 7170 / +91 8087042414 Email: help@grandresearchstore.com Follow Us On linkedin :- https://www.linkedin.com/company/grand-research-store/

[pharmaphorumuk]

Merck’s last-resort antibiotic Recarbrio nears EU approval

Merck & Co/MSD’s three-drug antibiotic Recarbrio has been recommended for approval in Europe for Gram-negative infections, but should be reserved for use in patients with limited treatment options.

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) backed approval of Recarbrio at its meeting last week, a few months after the drug was approved by the FDA for complicated urinary tract and intra-abdominal infections (cIAI).

The new drug combines the active ingredients in MSD’s broad-spectrum antibiotic Primaxin (imipenem/cilastatin) with a new beta lactamase inhibitor called relebactam that is designed to restore susceptibility to imipenem in resistant strains.

Drugs in the carbapenem class like imipenem have become last-line treatments for a number of multidrug resistant (MDR) infections, so Recarbrio could offer a fallback option in people with serious infections.

The CHMP notes that Recarbrio should only be prescribed “after consultation with a physician with appropriate experience in the management of infectious diseases” and with consideration to “official guidance on the appropriate use of antibacterial agents.”

The drug targets Gram-negative pathogens like Enterobacter cloacea, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae and Pseudomonas aeruginosa.

Recarbrio’s reserved status means that it won’t be a big seller for MSD, with Cowen & Co analysts expecting sales to reach around $150 million in 2024, but it will be an important new option for patients.

The low returns on new antibiotic research have driven a lot of the multinational drugmakers out of the category, raising fears that MDR will become rampant and society could enter a post-antibiotic age where once-trivial infections can be life-threatening.

That disincentive is one of the factors behind a new UK proposal for a new payment system for antibiotics that will see companies paid upfront for access to new antibiotics based on their value to the NHS, rather than the volume of medicines sold.

Recarbrio was one of five new medicines recommended for approval by the CHMP at its latest meeting, along with Novartis’ wet age-related macular degeneration (AMD) therapy Beovu, Accord Healthcare’s generic versions of azacitidine for blood cancers and sedative dexmedetomidine, and Pfizer’s Amsparity – a biosimilar of AbbVie’s immunology blockbuster Humira (adalimumab).

There were also several new positive opinions on already-marketed drugs, including:

Janssen-Cilag’s Darzalex (daratumumab) for use in combination with Takeda’s Velcade (bortezomib), thalidomide and dexamethasone for adult patients with newly diagnosed multiple myeloma who are eligible for an autologous stem cell transplant;

A new 61 mg soft capsule formulation of Pfizer’s Vyndaqel (tafamidis) for the treatment of wild‑type or hereditary transthyretin amyloidosis in adult patients with transthyretin amyloid cardiomyopathy (ATTR-CM);

Extending the age-range for children with plaque psoriasis eligible for treatment with Janssen-Cilag’s Stelara (ustekinumab) to six years and over from 12 and over;

Extending the age range for treatment with Janssen-Cilag’s pulmonary multidrug‑resistant tuberculosis (MDR‑TB) therapy Sirturo (bedaquiline) to include adolescents aged over 12 as well as adults;

New oral and intravenous infusion formulations of Helsinn Birex Pharma’s Akynzeo (fosnetupitant/palonosetron) for prevention of chemotherapy-induced nausea and vomiting (CINV);

Eli Lilly’s Cyramza (ramucirumab) in combination with Roche’s Tarceva (erlotinib) for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating EGFR mutations;

A new film-coated formulation of Astellas’ Dificlir (fidaxomicin) that extends the use of the Clostridioides difficile infection (CDI) drug to include children weighing over 12.5 kg as well as adults.

The post Merck’s last-resort antibiotic Recarbrio nears EU approval appeared first on .

from https://pharmaphorum.com/news/mercks-last-resort-antibiotic-recarbrio-nears-eu-approval/